[go: up one dir, main page]

LT2003001A - Nuo ciklinų priklausomų kinazių n-[5-[[[5-alkil-2-oxazolil]metil]tio]-2-tiazolil]karboksamido inhibitoriai - Google Patents

Nuo ciklinų priklausomų kinazių n-[5-[[[5-alkil-2-oxazolil]metil]tio]-2-tiazolil]karboksamido inhibitoriai

Info

Publication number
LT2003001A
LT2003001A LT2003001A LT2003001A LT2003001A LT 2003001 A LT2003001 A LT 2003001A LT 2003001 A LT2003001 A LT 2003001A LT 2003001 A LT2003001 A LT 2003001A LT 2003001 A LT2003001 A LT 2003001A
Authority
LT
Lithuania
Prior art keywords
oxazolyl
thiazolyl
thio
alkyl
methyl
Prior art date
Application number
LT2003001A
Other languages
English (en)
Other versions
LT5106B (lt
Inventor
Raj N. Misra
Hai Yun Xiao
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of LT2003001A publication Critical patent/LT2003001A/lt
Publication of LT5106B publication Critical patent/LT5106B/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Šiame išradime yra aprašomi junginiai, kurių formulė I, jų enantiomerai, diastereomerai ir farmaciškai priimtinos druskos. I formulės junginiai yra proteinkinazės inhibitoriai ir tinka proliferacinėms ligoms, pavyzdžiui, vėžiui, uždegimams ir artritui, gydyti. Jie taip pat gali būti tinkami Alchaimerio ligai, chemoterapijos sukeltam nuplikimui ir širdies ir kraujagyslių ligai gydyti.ą
LT2003001A 2000-07-26 2003-01-07 Nuo ciklinų priklausomų kinazių n-[5-[[[5-alkil-2-oxazolil]metil]tio]-2-tiazolil]karboksamido inhibitoriai LT5106B (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61662700A 2000-07-26 2000-07-26
US09/746,060 US6414156B2 (en) 1998-10-21 2000-12-22 Process for preparing azacycloalkanoylaminothiazoles

Publications (2)

Publication Number Publication Date
LT2003001A true LT2003001A (lt) 2003-11-25
LT5106B LT5106B (lt) 2004-02-25

Family

ID=27087817

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2003001A LT5106B (lt) 2000-07-26 2003-01-07 Nuo ciklinų priklausomų kinazių n-[5-[[[5-alkil-2-oxazolil]metil]tio]-2-tiazolil]karboksamido inhibitoriai

Country Status (21)

Country Link
US (3) US6414156B2 (lt)
EP (1) EP1303514B9 (lt)
JP (1) JP2004505080A (lt)
KR (1) KR100764949B1 (lt)
CN (1) CN1227250C (lt)
AT (1) ATE299878T1 (lt)
AU (1) AU5936901A (lt)
BR (1) BR0112748A (lt)
CA (1) CA2417260A1 (lt)
CY (1) CY1105666T1 (lt)
CZ (1) CZ2003239A3 (lt)
DE (1) DE60112091T2 (lt)
DK (1) DK1303514T3 (lt)
ES (1) ES2245984T3 (lt)
HU (1) HUP0301649A3 (lt)
IL (2) IL153748A0 (lt)
LT (1) LT5106B (lt)
MX (1) MXPA03000685A (lt)
PL (1) PL365464A1 (lt)
PT (1) PT1303514E (lt)
WO (1) WO2002010163A1 (lt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6414156B2 (en) 1998-10-21 2002-07-02 Bristol-Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles
US6392053B2 (en) 1999-12-15 2002-05-21 Bristol-Myers Squibb Company Process for preparing arylacetylaminothiazoles
US6534531B2 (en) * 2000-04-27 2003-03-18 Bristol-Myers Squibb Company Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy
HRP20030116A2 (en) * 2000-07-26 2005-02-28 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]carboxamide inhibitors of cyclin dependent kinases
DE10300124A1 (de) * 2003-01-07 2004-07-15 Bayer Ag Verfahren zur Herstellung von Arylalkinen
BRPI0513405A (pt) * 2004-07-16 2008-05-06 Sunesis Pharmaceuticals Inc tienopirimidinas úteis como inibidores de aurora quinase
EP2044066A2 (en) * 2006-06-06 2009-04-08 Bristol-Myers Squibb Company Crystalline forms of n-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl] thio]-2-thiazolyl]-4-piperidinecarboxamide
TW200922564A (en) * 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
WO2010075542A1 (en) 2008-12-23 2010-07-01 Curis, Inc. Cdk inhibitors
EP3384897A1 (de) * 2017-04-03 2018-10-10 Covestro Deutschland AG Kosmetische zusammensetzungen mit speziellen carbodiimiden für haare

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1088049A (en) 1975-06-03 1980-10-21 Takashi Masugi 3-substituted-7-substituted alkanamido-3-cephem-4- carboxylic acid compounds and processes for preparation thereof
CA1201431A (en) 1981-12-17 1986-03-04 Daiei Tunemoto .beta.-LACTAM COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND INTERMEDIATE PRODUCTS FOR THE PREPARATION THEREOF
NO831160L (no) 1982-04-08 1983-10-10 Erba Farmitalia Fremstilling av substituerte penem-derivater
JPS6339868A (ja) 1986-08-04 1988-02-20 Otsuka Pharmaceut Factory Inc ジ低級アルキルフエノ−ル誘導体
TW205041B (lt) 1989-08-07 1993-05-01 Fujisawa Pharmaceutical Co
DE4119756A1 (de) 1991-06-15 1992-12-17 Basf Ag Aminoalkylsubstituierte 5-mercaptothiazole, ihre herstellung und verwendung
US5491157A (en) 1993-05-10 1996-02-13 Eastman Kodak Company Method and composition for the prevention, control and amelioration of soilborne fungi and disease caused thereby
IL112721A0 (en) 1994-03-10 1995-05-26 Zeneca Ltd Azole derivatives
JPH0859669A (ja) 1994-06-13 1996-03-05 Takeda Chem Ind Ltd セフェム化合物、その製造法及び剤
EP0796263A1 (en) 1994-12-09 1997-09-24 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds and pharmaceutical use thereof
IL117620A0 (en) 1995-03-27 1996-07-23 Fujisawa Pharmaceutical Co Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same
AUPN801196A0 (en) 1996-02-12 1996-03-07 Fujisawa Pharmaceutical Co., Ltd. New cephem compounds and pharmaceutical use thereof
DE69835241T2 (de) 1997-10-27 2007-05-31 Agouron Pharmaceuticals, Inc., La Jolla 4-Aminothiazol Derivate, deren Herstellung und deren Verwendung als Inhibitoren Cyclin-abhängiger Kinasen
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6414156B2 (en) 1998-10-21 2002-07-02 Bristol-Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles
US6214852B1 (en) 1998-10-21 2001-04-10 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
GB9823871D0 (en) 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
MY125768A (en) 1999-12-15 2006-08-30 Bristol Myers Squibb Co N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6534531B2 (en) 2000-04-27 2003-03-18 Bristol-Myers Squibb Company Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy
HRP20030116A2 (en) 2000-07-26 2005-02-28 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]carboxamide inhibitors of cyclin dependent kinases

Also Published As

Publication number Publication date
CY1105666T1 (el) 2010-12-22
CZ2003239A3 (cs) 2003-08-13
US20040063767A1 (en) 2004-04-01
MXPA03000685A (es) 2003-09-10
EP1303514B1 (en) 2005-07-20
ATE299878T1 (de) 2005-08-15
US6897321B2 (en) 2005-05-24
US20010006976A1 (en) 2001-07-05
PT1303514E (pt) 2005-11-30
AU5936901A (en) 2002-02-13
KR20030064736A (ko) 2003-08-02
PL365464A1 (en) 2005-01-10
ES2245984T3 (es) 2006-02-01
DK1303514T3 (da) 2005-10-10
HUP0301649A2 (hu) 2003-12-29
HUP0301649A3 (en) 2008-04-28
IL153748A (en) 2009-07-20
CA2417260A1 (en) 2002-02-07
EP1303514A1 (en) 2003-04-23
EP1303514B9 (en) 2006-11-08
LT5106B (lt) 2004-02-25
US6414156B2 (en) 2002-07-02
US20020099217A1 (en) 2002-07-25
KR100764949B1 (ko) 2007-10-08
IL153748A0 (en) 2003-07-06
DE60112091T2 (de) 2006-04-20
HK1052928A1 (en) 2003-10-03
US6639074B2 (en) 2003-10-28
WO2002010163A1 (en) 2002-02-07
CN1227250C (zh) 2005-11-16
JP2004505080A (ja) 2004-02-19
CN1449395A (zh) 2003-10-15
BR0112748A (pt) 2003-09-09
DE60112091D1 (de) 2005-08-25

Similar Documents

Publication Publication Date Title
TWI265930B (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
BG107468A (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases
MY125768A (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
EA200300248A1 (ru) Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
DE60214703D1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
MXPA03010961A (es) Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
ATE536353T1 (de) 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren
NO20004803L (no) Smilagening og anzurogenin for behandling av Alzheimers sykdom
NO2008019I1 (no) N-[2-(dietylamino)etyl]-5-[(Z)-(5-fluoro-2-okso-L,2-dihydro-3H-indol-3-yliden)metyl]-2,4-dimetyl-LH-pyrrol-3-karboksamid (sunitinib),samt farmasoeytisk akseptable salter
MXPA02005844A (es) Inhibidores de cinasas de proteina.
WO2002085909A8 (en) 9-deazaguanine derivatives as inhibitors of gsk-3
DE60326646D1 (de) Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen
BR9908332A (pt) Derivados de n-[carbonil(anel di ou triaza diinsaturado de cinco membros substituìdo)] derivados de guanidina para tratamento de esquemia
AU2002314914A1 (en) Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
MY135477A (en) 2-(2,6-dichlorophenyl)-diarylimidazoles
AU2002310187A1 (en) Inhibitors of protein kinase for the treatment of disease
IT1256282B (it) Composizione farmaceutica che comprende una particolare forma fisica di un derivato di un'ammide eterociclica
MA27561A1 (fr) Derives d'aminoindazoles et leur utilisation comme inhibiteurs de kinases
MY119997A (en) Mesylate dihydrate salts of 5-(2-(4-(1, 2-benzisothiazol-3-yl) -1-piperazinyl)-6-chloro-1, 3- dihydro-2h-indol-2-one
EP1689713A4 (en) BENZYL ETHER AND BENZYLAMINE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER DISEASE
LT2003001A (lt) Nuo ciklinų priklausomų kinazių n-[5-[[[5-alkil-2-oxazolil]metil]tio]-2-tiazolil]karboksamido inhibitoriai
BRPI0407841A (pt) inibidores heterocìclicos de quinase
GEP20074045B (en) (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
AU2972701A (en) 3-aminopyrazole inhibitors of cyclin dependent kinases
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20100509